Advisory post highlighting the potential for divergence between drug-drug interaction warning severity levels assigned by Cegedim Healthcare Solutions and those included in the BNF and Stockley’s information for interactions.
Latest News
Oxybutynin 3.9mg/24hours transdermal patches was marked as discontinued in dm+d in August 2021. This means that once the September Gemscript update was installed, you could no longer prescribe it as an NHS prescription in Vision 3 or Vision Anywhere.
When you add a medication, Vision 3 automatically runs specific drug checks depending on your set up. It is important for patient safety that Drug Checks are set up effectively. The Benefits of Automatic Drug Checks guide details the available checks and how to set them up within Vision 3.